Promising lymphoma drug trial halted early after enrolling only 3 patients
NCT ID NCT04486391
First seen Nov 16, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This study tested a drug called tislelizumab against standard chemotherapy for people with classical Hodgkin lymphoma that returned or didn't respond to prior treatments. Only 3 people took part before the study was stopped early. The goal was to see if tislelizumab could delay cancer growth better than chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
-
Quanzhou First Affliated Hospital of Fujian Medical University
Quanzhou, Fujian, 362000, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.